A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation

Trial Profile

A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Glycopyrrolate (Primary) ; Indacaterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Registrational
  • Acronyms GEM3
  • Sponsors Novartis
  • Most Recent Events

    • 01 Jun 2016 Results published in the Respiratory Medicine
    • 20 Jan 2015 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov.
    • 07 Oct 2014 Planned End Date changed from 1 Dec 2014 to 1 Nov 2014, according to ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top